PURPOSE OF REVIEW: Antibiotic dosing for critically ill patients that is derived from other patient groups is likely to be suboptimal because of significant antibiotic pharmacokinetic changes, particularly in terms of drug volume of distribution and clearance. Organ support techniques including renal replacement therapy (RRT) and extracorporeal membrane oxygenation (ECMO) increase the pharmacokinetic variability. This article reviews the recently published antibiotic pharmacokinetic data associated with burns patients, those receiving continuous RRT (CRRT), sustained low-efficiency dialysis (SLED) and ECMO. RECENT FINDINGS: These groups develop increases in volume of distribution that necessitate the use of higher initial doses to rapidly achieve therapeutic antibiotic concentrations. Burns patients have supranormal drug clearances requiring more frequent administration of antibiotics. Patients receiving CRRT or SLED have variable drug clearances related to different equipment and RRT settings at different institutions. ECMO presents a different challenge because there is such a dearth of data with higher than standard doses potentially required, even in the presence of end-organ failure. SUMMARY: In the context of such variable pharmacokinetics, a guideline approach to dosing remains elusive because of insufficient available data and, therefore, use of therapeutic drug monitoring should be considered advantageous where possible.
PURPOSE OF REVIEW: Antibiotic dosing for critically illpatients that is derived from other patient groups is likely to be suboptimal because of significant antibiotic pharmacokinetic changes, particularly in terms of drug volume of distribution and clearance. Organ support techniques including renal replacement therapy (RRT) and extracorporeal membrane oxygenation (ECMO) increase the pharmacokinetic variability. This article reviews the recently published antibiotic pharmacokinetic data associated with burns patients, those receiving continuous RRT (CRRT), sustained low-efficiency dialysis (SLED) and ECMO. RECENT FINDINGS: These groups develop increases in volume of distribution that necessitate the use of higher initial doses to rapidly achieve therapeutic antibiotic concentrations. Burns patients have supranormal drug clearances requiring more frequent administration of antibiotics. Patients receiving CRRT or SLED have variable drug clearances related to different equipment and RRT settings at different institutions. ECMO presents a different challenge because there is such a dearth of data with higher than standard doses potentially required, even in the presence of end-organ failure. SUMMARY: In the context of such variable pharmacokinetics, a guideline approach to dosing remains elusive because of insufficient available data and, therefore, use of therapeutic drug monitoring should be considered advantageous where possible.
Authors: T Tängdén; V Ramos Martín; T W Felton; E I Nielsen; S Marchand; R J Brüggemann; J B Bulitta; M Bassetti; U Theuretzbacher; B T Tsuji; D W Wareham; L E Friberg; J J De Waele; V H Tam; Jason A Roberts Journal: Intensive Care Med Date: 2017-04-13 Impact factor: 17.440
Authors: Vesa Cheng; Mohd H Abdul-Aziz; Fay Burrows; Hergen Buscher; Young-Jae Cho; Amanda Corley; Arne Diehl; Eileen Gilder; Stephan M Jakob; Hyung-Sook Kim; Bianca J Levkovich; Sung Yoon Lim; Shay McGuinness; Rachael Parke; Vincent Pellegrino; Yok-Ai Que; Claire Reynolds; Sam Rudham; Steven C Wallis; Susan A Welch; David Zacharias; John F Fraser; Kiran Shekar; Jason A Roberts Journal: Antimicrob Agents Chemother Date: 2021-08-30 Impact factor: 5.191
Authors: Vesa Cheng; Mohd H Abdul-Aziz; Fay Burrows; Hergen Buscher; Young-Jae Cho; Amanda Corley; Arne Diehl; Eileen Gilder; Stephan M Jakob; Hyung-Sook Kim; Bianca J Levkovich; Sung Yoon Lim; Shay McGuinness; Rachael Parke; Vincent Pellegrino; Yok-Ai Que; Claire Reynolds; Sam Rudham; Steven C Wallis; Susan A Welch; David Zacharias; John F Fraser; Kiran Shekar; Jason A Roberts Journal: Antimicrob Agents Chemother Date: 2021-10-11 Impact factor: 5.938
Authors: Hannah Yejin Kim; Kenneth C Byashalira; Scott K Heysell; Anne-Grete Märtson; Stellah G Mpagama; Prakruti Rao; Marieke G G Sturkenboom; Jan-Willem C Alffenaar Journal: Ther Drug Monit Date: 2022-02-01 Impact factor: 3.118
Authors: A Brinkmann; A C Röhr; A Köberer; T Fuchs; J Preisenberger; W A Krüger; O R Frey Journal: Med Klin Intensivmed Notfmed Date: 2016-09-13 Impact factor: 0.840
Authors: Anne M Lachiewicz; Christopher G Hauck; David J Weber; Bruce A Cairns; David van Duin Journal: Clin Infect Dis Date: 2017-11-29 Impact factor: 9.079
Authors: Jason A Roberts; Mohd H Abdul-Aziz; Jeffrey Lipman; Johan W Mouton; Alexander A Vinks; Timothy W Felton; William W Hope; Andras Farkas; Michael N Neely; Jerome J Schentag; George Drusano; Otto R Frey; Ursula Theuretzbacher; Joseph L Kuti Journal: Lancet Infect Dis Date: 2014-04-24 Impact factor: 25.071